{"prompt": "['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 34 of 61', 'Medtronic', 'aware of the deviation. Site personnel should work with subjects to ensure subject follow-up visits are', 'scheduled within the visit window; however, any visits completed outside of the visit window will', 'require a protocol deviation to be reported. All protocol deviations must be reported on the Protocol', \"Deviation eCRF after the site's awareness of the deviation.\", 'The sponsor may choose to terminate the study at a site for failure to follow the written protocol and', 'investigator agreement. If this occurs, the Investigator, IRB/EC and governing regulatory authority (if', 'applicable) will be notified in writing of the reasons for the termination.', '9.11. Subject Withdrawal or Discontinuation', 'Subjects are free to voluntarily withdraw from the study at any time and for any reason. All implanted', 'subjects will be followed until the 12-week follow-up visit, unless withdrawn from the study. Withdrawn', 'or exited subjects will be followed under normal medical practice.', 'Examples of reasons for study discontinuation include, but are not limited to, those listed below:', 'If the subject does not meet eligibility criteria of at least 3 UUI episodes demonstrated on a 3-', 'day baseline urinary voiding diary', 'Subject death', 'Subject lost to follow-up', 'Subject voluntarily withdraws from the study', 'Subject becomes pregnant', \"Investigator terminates the subject's participation in the study due to lack of compliance,\", 'violation of/change in eligibility criteria', 'Any clinical laboratory abnormality, current illness, or other medical condition or situation', 'occurs such that continued study participation would not be in the best interest of the subject.', 'Subject is not a candidate for InterStim Therapy', 'Normal study completion', \"Prior to deeming a subject lost to follow-up, telephone calls must be documented in the subject's\", 'medical record. If a minimum of three attempts to contact the subject have failed (e.g. phone and', 'mailed letter), and no response is received, the site should exit the subject and complete the Study Exit', 'eCRF.', 'When a subject is withdrawn from the study, the Study Exit eCRF is to be completed and should include', 'detailed notes as to why the subject was withdrawn from the study (e.g., discomfort, lack of efficacy,', 'diary too burdensome). Withdrawn subjects will not be replaced.', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 35 of 61', 'Medtronic', \"Once a subject completes participation in the study, follow-up will continue in accordance with the site's\", 'standard of care. No study specific medical care will be provided for a subject after discontinuation', 'from the study, unless outlined in the Clinical Trial Agreement and Informed Consent Form.', '10. Risks and Benefits', '10.1. Potential Risks', 'The risks outlined below are the same risks found in commercial InterStim II System use; however,', 'based on the amplitude settings, subjects may experience less than desired improvements in OAB', 'symptoms. No additional study specific risks are present.', '10.1.1. Risks Outlined in the Instructions for Use (IFU)', 'Refer to the appropriate Instructions for Use (IFU) for the InterStim System components for updated list', 'on contraindications, precautions, warnings, adverse events, directions for use and other product', 'specific details.', 'In addition to the risks normally associated with surgery, implantation, or use of a neurostimulation', 'system includes, but is not limited to, the following risks. Certain adverse events may necessitate', 'surgical intervention.', 'Adverse change in voiding function (bowel and/or bladder)', 'Allergic or immune system response to the implanted materials that could result in', 'device rejections', 'Change in sensation of stimulation which has been described as uncomfortable (jolting', 'or shocking) by some patients', 'Infection', 'New pain', 'Pain at neurostimulator and or lead site', 'Seroma, hemorrhage, hematoma', 'Suspected lead or neurostimulator migration or erosion', 'Suspected nerve injury', 'Suspected technical device problem', 'Transient electric shock', 'The safety of SNM has not been established for pregnant women, for an unborn fetus, or during', 'childbirth. This precaution is provided in the InterStim Therapy commercial labeling and should be', 'adopted in this study; thus, no one who is pregnant or planning to become pregnant will be enrolled.', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']\n\n###\n\n", "completion": "END"}